Crizanlizumab

Summary

Crizanlizumab (CHEMBL4297734) is an approved antibody (ATC B06AX01) targeting SELP; indicated across 4 conditions including sickle cell disease and priapism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: B06AX01
• Targets: 1 (SELP)
• Indications: 4 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297734
Name	Crizanlizumab
Type	Antibody
Max phase	4
ATC	B06AX01

Also known as: Adakveo, Crizanlizumab, Crizanlizumab tmca, Crizanlizumab-tmca, NVP-LXI-262, NVP-LXI262, SEG-101, SEG101, SEL-G1, Selg1, SelG1, CRIZANLIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SELP	selectin P (CD62)	Binding	8.23		P16109

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SELP.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SELP
Platelet degranulation	1	SELP
Cell surface interactions at the vascular wall	1	SELP
Platelet activation, signaling and aggregation	1	SELP
Response to elevated platelet cytosolic Ca2+	1	SELP

Dominant GO biological processes

GO term	Targets
positive regulation of leukocyte migration	1
inflammatory response	1
cell adhesion	1
heterophilic cell-cell adhesion	1
leukocyte cell-cell adhesion	1
positive regulation of platelet activation	1
calcium-dependent cell-cell adhesion	1
response to lipopolysaccharide	1
regulation of integrin activation	1
response to cytokine	1
defense response to Gram-negative bacterium	1
leukocyte tethering or rolling	1
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
cell-cell adhesion	1
positive regulation of leukocyte tethering or rolling	1

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sickle cell disease	4	MONDO:0011382	MONDO:0011382
priapism	2	MONDO:0004745	HP:0200023
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
primary myelofibrosis	1	MONDO:0009692	MONDO:0044903

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	7
Not specified	4
PHASE4	3
PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04657822	PHASE4	RECRUITING	Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04505774	PHASE4	COMPLETED	Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
NCT04662931	PHASE4	COMPLETED	An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
NCT03814746	PHASE3	ACTIVE_NOT_RECRUITING	Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT06439082	PHASE3	RECRUITING	A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT05469828	PHASE1/PHASE2	NOT_YET_RECRUITING	Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
NCT05909618	PHASE2	RECRUITING	Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
NCT01895361	PHASE2	COMPLETED	Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
NCT03264989	PHASE2	COMPLETED	Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
NCT03474965	PHASE2	COMPLETED	Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
NCT03938454	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
NCT04097821	PHASE1/PHASE2	TERMINATED	Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
NCT04435184	PHASE2	COMPLETED	Crizanlizumab for Treating COVID-19 Vasculopathy
NCT04611880	PHASE2	COMPLETED	Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
NCT03720626	Not specified	AVAILABLE	Managed Access Programs for SEG101, Crizanlizumab
NCT05020873	Not specified	TERMINATED	Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
NCT05334576	Not specified	UNKNOWN	Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
NCT05494541	Not specified	COMPLETED	Characteristics of Patients With Sickle Cell Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
GALLIC ACID	ChEMBL + PubChem	Phase 2 (approved)	SELP
BIMOSIAMOSE	ChEMBL	Phase 2	SELP